Alba Rivera

Dr. Alba Rivera

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
EBEster del Barrio-Tofiño
Ester del Barrio-Tofiño
CLCarla López-Causapé
Carla López-Causapé
GCGabriel Cabot
Gabriel Cabot
ARAlba Rivera
Alba Rivera
Natividad BenitoNatividad Benito
Natividad Benito
AOAntonio Oliver
Antonio Oliver
This study assessed the molecular epidemiology, resistance mechanisms, and susceptibility profiles of a collection of 150 extensively drug-resistant (XDR) Pseudomonas aeruginosa clinical isolates obtained from a 2015 Spanish multicenter study, with a particular focus on resistome analysis in relation to ceftolozane-tazobactam susceptibility. Broth microdilution MICs revealed that nearly all (>95%) of the isolates were nonsusceptible to piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, and ciprofloxacin. Most of them were also resistant to tobramycin (77%), whereas nonsusceptibility rates were lower for ceftolozane-tazobactam (31%), amikacin (7%), and colistin (2%). Pulsed-field gel electrophoresis–multilocus sequence typing (PFGE-MLST) analysis revealed that nearly all of the isolates belonged to previously described high-risk clones. Sequence type 175 (ST175) was detected in all 9 participating hospitals and accounted for 68% ( n = 101) of the XDR isolates, distantly followed by ST244 ( n = 16), ST253 ( n = 12), ST235 ( n = 8), and ST111 ( n = 2), which were detected only in 1 to 2 hospitals. Through phenotypic and molecular methods, the presence of horizontally acquired carbapenemases was detected in 21% of the isolates, mostly VIM (17%) and GES enzymes (4%). At least two representative isolates from each clone and hospital ( n = 44) were fully sequenced on an Illumina MiSeq. Classical mutational mechanisms, such as those leading to the overexpression of the β-lactamase AmpC or efflux pumps, OprD inactivation, and/or quinolone resistance-determining regions (QRDR) mutations, were confirmed in most isolates and correlated well with the resistance phenotypes in the absence of horizontally acquired determinants. Ceftolozane-tazobactam resistance was not detected in carbapenemase-negative isolates, in agreement with sequencing data showing the absence of ampC mutations. The unique set of mutations responsible for the XDR phenotype of ST175 clone documented 7 years earlier were found to be conserved, denoting the long-term persistence of this specific XDR lineage in Spanish hospitals. Finally, other potentially relevant mutations were evidenced, including those in penicillin-binding protein 3 (PBP3), which is involved in β-lactam (including ceftolozane-tazobactam) resistance, and FusA1, which is linked to aminoglycoside resistance.

1 April 2013 in Microbial Drug Resistance
Verified
Journal Article
Closed access
EMELISENDA MIRO
ELISENDA MIRO
FGFederico Grünbaum
Federico Grünbaum
LGLaura Gómez
Laura Gómez
ARAlba Rivera
Alba Rivera
BMBeatriz Mirelis
Beatriz Mirelis
Ferran NavarroFerran Navarro
Ferran Navarro
A total of 788 clinical Enterobacteriaceae were collected to describe the aminoglycoside-modifying genes (AME genes) and to characterize the plasmids that carry these genes. Among the 788 strains collected, 330 (41.8%) were aminoglycoside-resistant: 264 Escherichia coli (80%), 33 Proteus mirabilis (10%), 10 Klebsiella pneumoniae (3%), six K. oxytoca (1.8%), five Enterobacter cloacae (1.5%), three Morganella morganii (0.9%), three Providencia stuartii (0.9%), two Salmonella enterica (0.6%), and one each Citrobacter freundii , C. koseri , Proteus vulgaris , and Shigella sonnei . The most affected aminoglycoside was streptomycin (92.7%), followed by kanamycin (26.3%), gentamicin (18%), tobramycin (16.9%), netilmicin (3.6%), and amikacin (1.5%). The AME genes found were aph(3″)-Ib (65.4%), ant(3″)-Ia (37.5%), aph(3′)-Ia (13.9%), aac(3)-IIa (12.4%), aac(6′)-Ib (4.2%), ant(2″)-Ia (3.6%), and aph(3′)-IIa (1.2%). Thirty-four percent of the strains showed more than one enzyme. The most frequent association was ant(3″)-Ia plus aph(3″)-Ib (35 strains). From 66 selected AME genes, 24 were plasmid located: 12 aac(3)-IIa , six aph(3′)-Ia , three ant(3″)-Ia , two ant(2″)-Ia , and one aac(6′)-Ib . These genes were located in plasmids belonging to incompatibility groups F, FIA, FIB, or HI2. In conclusion, the AME genes involved in aminoglycoside-clinical resistance were aac(3)-IIa , aac(6′)-Ib , and ant(2″)-Ia , genes that confer resistance to tobramycin, gentamicin, and amikacin.

1 August 2006 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
PDF file
ARAlba Rivera
Alba Rivera
MRMontserrat Rebollo
Montserrat Rebollo
EMELISENDA MIRO
ELISENDA MIRO
MMMíriam Mateo
Míriam Mateo
Ferran NavarroFerran Navarro
Ferran Navarro
PCPere Coll
Pere Coll
Group A streptococcus (GAS) has been described as an emerging cause of severe invasive infections. A retrospective hospital-based study was conducted, including GAS isolates causing invasive or non-invasive infections from January 1999 to June 2003 in Barcelona. Demographic and clinical information on the invasive cases was obtained from medical files. GAS isolates collected from 27 patients with invasive infections and 99 patients with non-invasive infections were characterized by emm type and subtype, superantigen (SAg) gene profile (speA–C, speF–J, speL, speM, ssa and smeZ), allelic variants of speA and smeZ genes, antibiotic susceptibility and genetic resistance determinants. The most prevalent emm type was emm1 (17.5 %), followed by emm3 (8.7 %), emm4 (8.7 %), emm12 (7.1 %) and emm28 (7.1 %). The smeZ allele and SAg gene profiles were closely associated with the emm type. The speA2, speA3 and speA4 alleles were found in emm1, emm3 and emm6 isolates, respectively. Overall, 27.8, 25.4 and 11.9 % of isolates were resistant to erythromycin, tetracycline or both agents, respectively. Reduced susceptibility to ciprofloxacin and levofloxacin (MIC 2–4 μg ml−1) was found in 3.2 % of isolates. mef(A)-positive emm types 4, 12 and 75, and erm(B)-positive emm types 11 and 25 were responsible for up to 80 % of the erythromycin-resistant isolates. No significant differences in emm-type distribution, SAg gene profile or resistance rates were found between invasive and non-invasive isolates. The SAg and antibiotic resistance genes appeared to be associated with the emm type and were independent of the disease type.

21 October 2005 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
EMELISENDA MIRO
ELISENDA MIRO
BMBeatriz Mirelis
Beatriz Mirelis
Ferran NavarroFerran Navarro
Ferran Navarro
ARAlba Rivera
Alba Rivera
RMRaúl Jesús Mesa
Raúl Jesús Mesa
PCPere Coll
Pere Coll
Objectives: The aim of the present study was to characterize and compare the extended-spectrum β-lactamase (ESBL)-producing organisms isolated from clinical samples and faecal carriers in 2001 and 2002. Methods: A total of 5251 Enterobacteriaceae isolated from clinical samples and 1321 stool samples were evaluated for the presence of ESBLs. The stool samples were spread onto plates of MacConkey agar containing 2 mg/L cefotaxime for selection of ESBL-producing strains. These strains were defined as those showing synergism between amoxicillin/clavulanic acid and third-generation cephalosporins. The β-lactamases involved were characterized by isoelectric focusing, PCR assays and DNA sequencing. Results: The prevalence of ESBL-producing strains among clinical Enterobacteriaceae was 1.7%. Of these, 87.6% produced CTX-M, 25.8% produced SHV and 2.2% were TEM-type-producing strains. All clinical ESBL-producing strains were Escherichia coli, with the exception of four Klebsiella pneumoniae and one Citrobacter freundii. The prevalence of faecal carriage of ESBL-producing organisms was 3.3%. Of these, 75% produced CTX-M-type enzymes followed by 22.7% SHV-producing strains. All faecal ESBL-producing strains were E. coli except for one Enterobacter cloacae and one Proteus mirabilis. This latter strain produced the PER-1 enzyme reported for the first time in Spain. Conclusions: The prevalence of ESBL-producing strains in stool samples was higher than that observed in clinical samples from the same period. The different types of ESBLs found were similar in both contexts. The most prevalent ESBLs were the CTX-M-related enzymes, with nine different types, followed by SHV-12.

31 March 2016 in Eurosurveillance
Verified
Journal Article
Open access
NPNúria Prim
Núria Prim
ARAlba Rivera
Alba Rivera
JRJudith Rodríguez-Navarro
Judith Rodríguez-Navarro
MEMontserrat Español
Montserrat Español
MTMiquel Turbau
Miquel Turbau
BMBeatriz Mirelis
Beatriz Mirelis
Colistin resistance was detected in 53 of 10,011 Escherichia coli (0.5%) by prospective phenotypic testing of consecutive clinical isolates in a single hospital in Barcelona, Spain (2012–15). The mcr-1 gene was retrospectively identified by PCR and sequencing in 15 of 50 available isolates. Each isolate had a unique PFGE pattern except for two. This clonal diversity supports the hypothesis of horizontal dissemination of the mcr-1 gene in the local study population.

1 December 2017 in Journal of Infection
Verified
Journal Article
Closed access
NPNúria Prim
Núria Prim
MTMiquel Turbau
Miquel Turbau
ARAlba Rivera
Alba Rivera
JRJudith Rodríguez-Navarro
Judith Rodríguez-Navarro
PCPere Coll
Pere Coll
BMBeatriz Mirelis
Beatriz Mirelis